qPharmetra Revenue and Competitors
Estimated Revenue & Valuation
- qPharmetra's estimated annual revenue is currently $2.1M per year.
- qPharmetra's estimated revenue per employee is $84,420
Employee Data
- qPharmetra has 25 Employees.
- qPharmetra grew their employee count by -7% last year.
qPharmetra Competitors & Alternatives
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.1M | 25 | -7% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $67.1M | 334 | 6% | N/A | N/A |
#4 | $25.5M | 127 | 55% | N/A | N/A |
#5 | $72.6M | 264 | -2% | $35M | N/A |
#6 | $3.3M | 40 | 48% | N/A | N/A |
#7 | $3.1M | 38 | -25% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $22.3M | 136 | 15% | $637.8K | N/A |
#10 | $44M | 219 | 8% | N/A | N/A |
What Is qPharmetra?
qPharmetra provides pharmacometric data analysis, strategic clinical pharmacology consulting to pharmaceutical and biotechnology organizations. Our services include NCA, population PK/PD Modeling and Simulation (M&S), Clinical Trial Simulations, Decision Analysis, preparation of regulatory documents (i.e. Modules 271, 272, 264). We hope you will consider us for your pharmacometric or clinical pharmacology and we look forward to speaking with you in the future. Please give us a call or write us a note for further information. Anja Henningsson, PhD CEO +46 70722 90 35 (M) anja.henningsson@qpharmetra.com Klaas Prins, PhD Head of Business Development +31 618 802 292 (M) klaas.prins@qpharmetra.com Lee Hodge, MBA CFO +1 919 324 5670 (M) lee.hodge@qpharmetra.com Lars Lindbom, PhD COO/CIO +46 707 229 035 (M) lars.lindbom@qpharmetra.com
keywords:N/AN/A
Total Funding
25
Number of Employees
$2.1M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.9M | 25 | 14% | N/A |
#2 | $3.1M | 25 | 39% | N/A |
#3 | $2.6M | 25 | 4% | N/A |
#4 | $4M | 25 | -17% | N/A |
#5 | $3.7M | 25 | 127% | N/A |